We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nouvelles approches dans les thérapeutiques ciblées: les récepteurs des facteurs de croissance de type insuline et les cyclines.
- Authors
Fleury, B.; Blay, J.-Y.; Fayette, J.
- Abstract
The spectrum of available targeted therapies widened with the introduction of insulin-like growth factor (IGF1R) and cyclin targeting. IGF1R is implicated in tumoural proliferation and resistance to apoptosis. Monoclonal antibodies or specific inhibitors of the tyrosine kinase for this receptor were developed and have demonstrated potential in preclinical and phase-I studies. The risk of these treatments is the interference with the biological function of insulin, in spite of strong specificity for IGF1R. The cyclins are implicated in the control of the cell cycle, especially its various points of restriction, which are defective in cancer cells. Cyclins are generally overexpressed in cancer cells, and their inhibition offers significant possibilities for new treatment regimes. The targeting of IGF1R or cyclins is relatively ineffective in monotherapy, but strongly potentiates the effects of cytotoxic chemotherapies.
- Subjects
CYCLINS; INSULIN receptors; PROTEIN kinases; IMMUNODIAGNOSIS of cancer; CANCER prevention; GROWTH factors; THERAPEUTICS
- Publication
Oncologie (Tech Science Press), 2006, Vol 8, Issue 9, p835
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-006-0540-x